R&D Tax Incentives in Life Sciences – Practical Insights into Claiming Overseas R&D Expenditure

8 January 2026

This webcast, hosted by our Life Sciences tax specialist Richard Turner, discussed practical insights on the new R&D tax regime derived from our research and client work over the course of 2025. During this session, we covered key topics such as:

• Evidencing CRO activities (when site-based and central costs are likely to be eligible)
• EPWs: potential considerations when engaged via a personal service company
• Thoughts on CMC expenditure and valid eligibility requirements
• Pre-clinical research within the overseas exemption
• Disclosure for the Additional Information Form

With reporting season approaching and the first year under the merged R&D tax regime drawing to a close, this session is particularly useful for UK-based Life Sciences businesses preparing claims under the new R&D regime and those involved in decision making and contracting with overseas suppliers.